Objectives: To establish prevalence rates of antipsychotic (AP) prescriptions for children 18 years of age or younger in British Columbia (BC) from 1996 to 2011 by age, sex, AP type, and primary diagnosis; and to identify the predominant AP prescribers for children by specialty training.
Clinical Implications
• The exponential rise in off-label SGA prescriptions to children and adolescents is of clinical concern given the literature demonstrating that these medications can lead to serious metabolic side effects.
• Knowledge translation initiatives promoting evidencebased prescribing and monitoring practices related to SGA treatment need to target all 3 prescriber groups and be tailored for age subgroups.
Limitations
• No data were available on inpatient AP prescriptions.
• Diagnoses were based on the prescribing physician's judgment, rather than by standardized research diagnostic techniques.
• As only one diagnostic code is required for physician remuneration, comorbid diagnoses are not submitted by the billing physician, and thus no data are available.
O ver the past 2 decades, prescriptions of APs, and more specifically, SGAs, for children and adolescents have increased substantially. 1 For example, the number of officebased visits by youth living in the United States that included an SGA-prescription increased 6-fold from 201 000 in 1993 to 1 224 000 in 2002. 2 In the United Kingdom, the overall prevalence of AP prescribing almost doubled between 1992 to 2005. 3 One reason proposed for this escalating trend of SGA prescriptions may be that there is a perception among prescribers of an improved side effect profile, compared with FGAs, particularly regarding extrapyramidal symptoms. 4 Notably, SGAs are commonly being used for a wide range of diagnoses not currently approved by the US Food and Drug Administration or Health Canada. 5, 6 The dramatic increase in off-label use of SGAs is of particular concern given the growing body of literature demonstrating that these medications may result in serious metabolic side effects, including weight gain, dyslipidemia, hypertension, type 2 diabetes, and metabolic syndrome in youth. 7, 8 Further, obesity and metabolic dysregulation in childhood poses an increased risk for long-term complications in adulthood, including cardiovascular disease. [9] [10] [11] [12] [13] Despite the established risks of SGA treatment, limited data 6, 14, 15 currently exist describing AP prescription trends in Canadian children. Alessi-Severini et al 6 recently published a report of prescribing APs to children in the province of Manitoba using administrative health databases. This report showed that prescriptions of APs for youth in Manitoba increased from 1.9 to 7.4 per 1000 population from 1999 to 2008. This study 6 also found that GPs were the main prescribers of SGAs to all youth and made up 73% of the prescriber population in 2008.
Currently, there are no available data describing SGA prescriber specialties by patient age group in the Canadian pediatric population. These data are essential for effective targeted dissemination of the recently published Canadian Méthodes : Les données administratives du ministère de la Santé de la C.-B. ont servi à décrire les prescriptions d'AP à des adolescents de 18 ans ou moins. Des comparaisons ont été effectuées au moyen de la prévalence de la population selon le sexe, le groupe d'âge, les AP, la 9e édition de la Classification internationale des maladies, le diagnostic, et la spécialité du prescripteur.
Résultats :
De 1996 à 2011, le taux global de prévalence des prescriptions d'AP (de la première et de la deuxième génération) a augmenté 3,8 fois (1,66 à 6,37 par 1000 de population); les prescriptions d'AP de deuxième génération (ADG) ont augmenté 18,1 fois (0,33 à 5,98 par 1000 de population). L'augmentation la plus élevée de toutes les prescriptions d'AP a touché les jeunes hommes de 13 à 18 ans (3,3 à 14,4 par 1000 de population; soit 4,4 fois plus), suivie par des augmentations semblables chez les garçons de 6 à 12 ans (2,3 à 8,6 par 1000 de population; soit 3,7 fois plus) et chez les filles de 13 à 18 ans (2,8 à 10,7 par 1000 de population; soit 3,8 fois plus). En général, les 3 diagnostics les plus communs associés à toutes les prescriptions d'AP étaient les troubles dépressifs (12, 8 clinical practice guidelines 16 for metabolic monitoring in SGA-treated youth, and the concomitant development of appropriate training resources for AP prescribers. Therefore, our study sought to 1) establish prevalence rates of AP prescriptions for children and adolescents 18 years and younger in BC from 1996 to 2011 by age, sex, AP type, and primary diagnosis, and 2) identify the predominant AP prescribers for children and adolescents by specialty training over this time period.
Method

Study Design
Our study protocol was approved by both the University of British Columbia Clinical Research Ethics Boards and the Children's and Women's Hospital Research Review Committee. The following data on APs (including SGAs: aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone; and FGAs: chlorpromazine, droperidol, flupenthixol, fluphenazine, haloperidol, mesoridazine, perphenazine, pimozide, prochlorperazine, promethazine, thioridazine, thiothixene, trifluoperazine, and zuclopenthixol) dispensed to all children and adolescents aged 18 years and younger (collectively referred to as youth) in BC were obtained from the PharmaNet database (the BC medication registry for all outpatient prescriptions): drug name, dose and quantity dispensed, duration of treatment, and prescriber information for each prescription. Youth were identified from the PharmaNet records by a personal health number, which is a unique identifier for each patient in BC, and prescribers were identified by their health services provider number contained in PharmaNet. The health services provider numbers were deterministically linked to each physician's specialty, and to the BC universal health insurance program (Medical Services Plan) billings using the Medical Services Plan billing number. For the few instances where the billing number was missing, probabilistic links were made, based on practitioner name and birth date.
Diagnoses were obtained from ICD-9 codes using probabilistic linkages between prescriptions and medical service claims. The top diagnoses included affective psychoses (ICD-9 296 to 296.9), anxiety or depression (ICD-9 50B), depressive disorder (ICD-9 311), disturbance of conduct not elsewhere classified (ICD-9 312 to 312.9), disturbance of emotions specific to childhood and adolescence (ICD-9 313 to 313.2), hyperkinetic syndrome of childhood (ICD-9 314 to 314.9), neurotic disorders (ICD-9 300 to 300.9), psychoses with origin specific to childhood (ICD-9 299 to 299.9), schizophrenic psychoses (ICD-9 295 to 295.9), and specific delays in development (ICD-9 315 to 315.9). Diagnoses were taken from youths' last visits to their prescribing physicians before prescriptions were dispensed. The top 5 diagnoses are reported for each age group (0 to 5 years, 6 to 12 years, and 13 to 18 years). The BC population estimates were obtained from BC Statistics. 17 Data are reported for each fiscal year (April 1 to March 31) from 1996/97 to 2010/11.
Analysis
Comparisons were made using population prevalence based on sex, age group, type of AP (FGA, compared with SGA), each SGA, psychiatric diagnoses, and prescribers' specialty training. Means were calculated directly from the dataset; as our study captured the entire BC pediatric population, odds ratios and confidence intervals were not applicable.
Results
The total number of youth who received an AP (either FGA or SGA) prescription increased from 1583 in 1996/97 to 5791 in 2010/11. This translates into a 3.8-fold increase in the overall AP prescription prevalence rate, from 1.66 per 1000 population in 1996/97 to 6.37 per 1000 population in 2010/11 ( Figure 1 ). The total number of youth who specifically received an SGA prescription increased from 315 in 1996/97 to 5432 in 2010/11. This represents an 18.1-fold increase in the prevalence rate of SGA prescriptions to youth, which increased from 0.33 per 1000 population in 1996/97 to 5.98 per 1000 population in 2010/11. Conversely, the absolute number of youth who received a FGA prescription decreased from 1366 (or 1.43 per 1000 population) in 1996/97 to 420 (or 0.46 per 1000 population) in 2010/11; this represents a 67% reduction in the agespecific rate over the same time period ( Figure 1 ). Figure 2 depicts the change in the numbers of unique patients who received an AP prescription (either SGA or FGA), by sex and age group. The highest age-specific rate of youth who received AP prescriptions was measured across males aged 13 to 18 years for whom the rate increased 4.4-fold from 3.3 per 1000 population in 1996/97 to 14.4 per 1000 population in 2010/11. Across the same time period, the age-specific rate for females aged 13 to 18 years increased 3.8-fold, from 2.8 per 1000 population to 10.7 per 1000 population. A similar 3.7-fold increase was measured for males aged 6 to 12 years for whom the agespecific rate increased from 2.3 per 1000 population to 8.6 per 1000 population. In contrast, the age-specific rate of females aged 6 to 12 years increased less dramatically (3.1-fold) from 0.90 per 1000 population in 1996/97 to 2.8 per 1000 population in 2010/11. For males aged 0 to 5 years, the age-specific rate increased slightly from 0.50 per 1000 population to 0.90 per 1000 population and for females aged 0 to 5 years the age-specific rate remained stable across the years at 0.30 per 1000 population.
AP Prescription Changes by Age and Sex
Types of APs Prescribed
In 1996/97, FGAs made up 76.3% of all AP prescriptions for youth. During this same fiscal year, the only 3 SGAs prescribed were risperidone, clozapine, and olanzapine, comprising 20.6%, 2.7%, and 0.4%, respectively, of all AP prescriptions for youth. By 2010/11, SGAs comprised 96.1% of all AP prescriptions for youth. The most frequently prescribed SGAs were risperidone (48.0%), quetiapine (36.2%), and olanzapine (5.9%). Other SGAs included aripiprazole (3.0%), clozapine (1.4%), ziprasidone (1.1%), and paliperidone (0.5%).
In 2010/11, FGAs comprised 3.9% of all AP prescriptions for youth. The most commonly prescribed FGAs were chlorpromazine (1.23%), loxapine succinate (0.74%), methotrimeprazine maleate (0.49%), pimozide (0.46%), haloperidol (0.38%), prochlorperazine maleate (0.30%), zuclopenthixol decanoate (0.12%), flupentixol decanoate (0.09%), pericyazine (0.08%), prochlorperazine (0.05%), and methotrimeprazine (0.02%).
AP Prescription Changes by Diagnosis
In total, 82% of all AP prescriptions in 2010/11 were linked to an ICD-9 diagnosis. Overall, the 3 most common diagnoses associated with all AP prescriptions were depressive disorders (12.8%), hyperkinetic syndrome of childhood (11.7%), and neurotic disorders (11.1%). Tables 1a through 1c provide a breakdown of diagnoses at the time of the first AP prescription, by practitioners' specialties. As of 2010/11, these data indicate that GPs prescribe APs most often for depression and anxiety (Table 1a) ; pediatricians prescribe APs most often for behavioural and emotionaltype disorders, as well as developmental delays (Table 1b) ; and psychiatrists prescribe APs most often for psychoses, anxiety states, depressive disorders, and behavioural disorders (Table 1c) .
Tables 2a through 2c indicate the most common diagnoses, stratified by age group at the time of the first prescription.
In 2010/11, the most common diagnosis associated with an AP prescription in children aged 0 to 5 years was hyperkinetic syndrome of childhood (20.7%), followed equally by disturbances of conduct (19%), disturbances of emotions specific to childhood (19%), and specific delays of development (19%). The most common diagnosis associated with AP prescriptions was hyperkinetic syndrome of childhood (32.0%) in children aged 6 to 12 years and depressive disorder (17.4%) in children aged 13 to 18 years. 
Prescription Changes by Prescriber Specialty
Discussion
We report a 3.8-fold increase in the number of new total AP prescriptions for children and adolescents in BC from 1996/97 to 2010/11. Notably, SGA prescriptions increased 18-fold during this time period. This is of great concern given the recent literature 7, 8 demonstrating that SGAs can lead to serious metabolic side effects that may predispose these youth to an increased risk of cardiovascular disease in adulthood. [10] [11] [12] [13] Our results are consistent with another recent Canadian study, 6 which documented a 4-fold increase in AP Our data revealed that the largest change in prescriptions was in 13-to 18-year-old males, with a 4.5-fold increase in AP prescriptions from 1996/97 to 2010/11. Consistent with these findings, Cooper et al 18 found a 116% increase in new AP prescriptions from 1996 to 2001 in 13-to 18-yearolds. In our study, males were significantly more likely to be prescribed an AP at an office visit than females. Further, there have been several other reports that males receive more prescriptions of APs than females. 2, 6, 19, 20 In addition to profound changes in prescriptions to older children, Cooper et al 21 found that schizophrenia and psychoses were the most common diagnoses associated with new AP prescriptions to youth living in the United States. In contrast, our data revealed a multitude of diagnoses for which APs are being prescribed, with important variations noted in different age subgroups; in BC, the most common diagnoses overall associated with an AP prescription were depressive disorders, hyperkinetic syndrome of childhood (an attention-deficit hyperactivity group disorder), and neurotic disorders. Our findings are more consistent with a recent Canadian report by Alessi-Severini et al, 6 who noted attention-deficit hyperactivity disorder, conduct disorder, and mood disorders as the most common diagnoses in children from Manitoba. The high rate of SGA prescriptions for depressive disorders in our study requires further exploration given that there is no evidence to support the use of SGAs for depression in children and adolescents. 5 In our paper, we uniquely describe prescriber specialty by age subgroups in children and adolescents. Our data reveal that SGAs are prescribed by different physician specialties for different diagnoses depending on specific age subgroups. In children aged 0 to 5 years, pediatricians continue to overwhelmingly remain the most common prescribers; in contrast, for children aged 6 to 12 years, GPs, psychiatrists, and pediatricians are now providing prescriptions in similar proportions. Finally, in 13-to 18-year-old youth, psychiatrists and GPs are the most common prescribers. These data highlight the need for tailored resources for prescribers of SGAs to this population. Further, prescriber information by age group is important for ensuring that prescriptions are for evidence-based diagnoses. These data are necessary for ensuring targeted and effective dissemination of the recently published national clinical practice guidelines for metabolic monitoring in SGAtreated children endorsed by the Canadian Academy of Child and Adolescent Psychiatry. 16
Strengths and Limitations
The BC Medical Services Plan is BC's universal health insurance program used by all BC residents, and therefore these data provide a complete evaluation of the use of health services in the population. Similarly, PharmaNet BC captures all outpatient prescriptions, regardless of payer. Both of these administrative datasets use a single unique identifier, the personal health number, with safeguards in place to verify the accuracy of the personal health number before a Medical Services Plan billing is paid or a medication is dispensed through PharmaNet BC. While this is an incredible strength of our paper, several limitations must be recognized. Eighty-two per cent of starting prescriptions were linked to a diagnosis. The remaining 18% of prescriptions were missing a diagnosis because the prescribing physicians were being remunerated through an alternate source (for example, alternate payment plan or sessional fees), and therefore were not required to submit a diagnosis as part of a Medical Services Plan billing. In those cases in which prescriptions were linked to a diagnosis, these diagnoses were based on the prescribing physician's judgment, rather than by standardized research diagnostic techniques. In addition, as only one diagnostic code is required for physician remuneration, comorbid diagnoses (for example, schizophrenia and insomnia) are not submitted by the billing physician. While this is a limitation, a strength of using these linked datasets is that the results were not affected by sampling errors or biased by limitations associated with insurance coverage. Another limitation is that these databases do not include data from prescriptions to youth in an inpatient setting, and therefore it will be important for future studies to include analysis of prescriptions from hospital pharmacies. Finally, while these data did include information about AP prescriber specialty, geographic location of prescribers (urban, compared with rural, compared with remote communities) was outside the scope of our paper.
Conclusions
There has been an exponential rise in SGA prescriptions in BC secondary to extensive off-label use, not only by psychiatrists, but also by family physicians and pediatricians. Knowledge translation initiatives promoting evidencebased prescribing and monitoring practices related to SGA treatment need to target the 3 main prescriber groups and be tailored for age subgroups. 
